公开(公告)号：US06514498B1

公开(公告)日：2003-02-04

申请号：US08695692

申请日：1996-08-12

申请人： Per Antonsson ,  Per Björk ,  Mikael Dohlsten ,  Johan Hansson ,  Göran Forsberg ,  Lars Abrahmsén ,  Terje Kalland

发明人： Per Antonsson ,  Per Björk ,  Mikael Dohlsten ,  Johan Hansson ,  Göran Forsberg ,  Lars Abrahmsén ,  Terje Kalland

IPC分类号： A61K3944

CPC分类号： C07K14/31 ,  A61K38/00 ,  A61K47/6817 ,  A61K47/6851 ,  A61K2039/505 ,  C07K16/3023 ,  C07K16/3046 ,  C07K19/00 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2319/00

摘要： A conjugate between a target-seeking moiety and a modified superantigen, characterized in that the superantigen is a wild-type superantigen (SA I) in which an amino acid residue in a superantigen region (region I) determining binding to TCR, referably TCRV&bgr;, and T cell activation has been replaced by another amino acid residue while retaining the ability to activate a subset of T cells. In a preferred embodiment the modified superantigen is a chimer between at least two wild-type superantigens (SA I, SA II etc) characterized in that one or more amino acid residues in a region determining binding to TCR and T cell activation have been interchanged between various wild-type superantigens. A therapeutic method making use of modified/chimeric superantigens as defined in the preceding paragraphs. An antibody preparation in which the cysteine residues that provide for interchain disulfide bonds have been mutated so as to forbid interchain disulfide bridges, preferably to serine residues, for use as a pharmaceutical.

摘要翻译： 靶寻求部分和修饰的超抗原之间的缀合物，其特征在于超抗原是野生型超抗原（SAI），其中确定结合TCR的超抗原区（区域I）中的氨基酸残基，可以指TCRVβ， 并且T细胞激活已被另一个氨基酸残基取代，同时保留激活T细胞亚群的能力。在优选实施方案中，修饰的超抗原是至少两种野生型超级抗原（SAI，SA II等）之间的嵌合体， 其特征在于确定结合TCR和T细胞活化的区域中的一个或多个氨基酸残基已经在各种野生型超级抗原之间互换.1。一种使用前述段落中定义的修饰/嵌合超级抗原的治疗方法。抗体制备 其中提供链间二硫键的半胱氨酸残基已被突变，以便禁止链间二硫键，优选为丝氨酸残基，用于 用作药物。